Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Liam Ratcliffe Biography and Net Worth

Director of Arvinas

Dr. Liam Ratcliffe M.D., Ph.D. serves as Independent Director of the Company. Dr. Ratcliffe has been Head of Access Biotechnology, a privately held group, since April 2019. From September 2008 to March 2019, Dr. Ratcliffe was a Managing Director and Member of New Leaf Venture Partners LLC, a venture capital firm. Previously, Dr. Ratcliffe was Senior Vice President and Development Head for Neuroscience, as well as Worldwide Head of Clinical Research and Development at Pfizer, a biopharmaceutical company. Dr. Ratcliffe currently serves on the board of directors of the publicly-traded company Passage Bio, Inc. and previously served on the board of directors of the publicly-traded companies Aptinyx, Inc., Array BioPharma Inc., Deciphera Pharmaceuticals, Inc., Edge Therapeutics, Inc. and Unum Therapeutics, Inc. Dr. Ratcliffe holds a Ph.D. in immunology and an M.D. from the University of Cape Town and an M.B.A. from the University of Michigan. Ratcliffe is qualified to serve on our board due to his extensive experience in the venture capital industry, his medical and scientific background and training, and his service on the boards of directors of public and private biopharmaceutical companies.

How do I contact Liam Ratcliffe?: The corporate mailing address for Dr. Ratcliffe and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Liam Ratcliffe's contact information.
Has Liam Ratcliffe been buying or selling shares of Arvinas?: Liam Ratcliffe has not been actively trading shares of Arvinas during the past quarter. Most recently, Liam Ratcliffe sold 85,705 shares of the business's stock in a transaction on Thursday, December 16th. The shares were sold at an average price of $69.36, for a transaction totalling $5,944,498.80. Learn More on Liam Ratcliffe's trading history.
Who are Arvinas' active insiders?: Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?: In the last year, insiders at the sold shares 3 times. They sold a total of 8,597 shares worth more than $404,488.85. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.
Information on this page was last updated on 2/23/2024.

Liam Ratcliffe Insider Trading History at Arvinas

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/16/2021	Sell	85,705	$69.36	$5,944,498.80
12/14/2021	Sell	156,464	$65.86	$10,304,719.04
11/15/2021	Sell	21,284	$84.87	$1,806,373.08
11/12/2021	Sell	39,869	$84.94	$3,386,472.86
11/10/2021	Sell	13,358	$88.20	$1,178,175.60
11/8/2021	Sell	81,054	$94.45	$7,655,550.30
11/5/2021	Sell	24,923	$91.30	$2,275,469.90
12/18/2020	Buy	142,857	$70.00	$9,999,990.00
11/12/2019	Buy	680,000	$22.00	$14,960,000.00

Liam Ratcliffe Buying and Selling Activity at Arvinas

Arvinas Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $22.69

$21.17

$22.71

50 Day Range

MA: $25.62

$21.64

$28.04

2 Week Range

Now: $22.69

$20.28

$53.08

Volume

744,090 shs

Average Volume

718,161 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96